Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health reported a strong Q2 2022 performance with $2.9 million in prescription product net revenue, a 12% increase quarter-over-quarter and a remarkable 641% rise year-over-year. The growth is attributed to a transition to a limited distribution network, reducing costs and enhancing Mytesi's gross-to-net ratio. Key initiatives include the ongoing OnTarget Phase 3 clinical trial for crofelemer and expected results from an investigator-initiated study for short bowel syndrome soon. Canalevia-CA1 for dogs also launched, showing promises in the veterinary market.
Jaguar Health (NASDAQ:JAGX) received a 180-day grace period from Nasdaq to regain compliance with the $1.00 bid price requirement, extending the deadline to February 13, 2023. To maintain its listing, Jaguar must achieve a closing bid price of at least $1.00 for ten consecutive business days. The company is focusing on two pivotal clinical activities in the next 6 to 12 months: a proof-of-concept study for crofelemer targeting short bowel syndrome and a Phase 3 trial for cancer therapy-related diarrhea, with expectations of significant value creation.
Jaguar Health, Inc. (NASDAQ:JAGX) will host an investor webcast on August 22, 2022, at 8:30 AM Eastern Time to present its second-quarter 2022 financial results and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ended June 30, 2022. Jaguar Health focuses on developing plant-based, non-opioid medications for gastrointestinal distress in both humans and animals. For more details and to register for the webcast, visit this link.
Jaguar Health has appointed Dr. Anula Jayasuriya to its Board of Directors as of July 1, 2022. With extensive experience in healthcare and investment, her expertise is expected to enhance Jaguar's efforts in gastrointestinal medicine development. The company also established a Business Development Advisory Committee, chaired by Rachel Zolot Schwartz, to explore partnerships and acquisitions. These strategic moves aim to strengthen Jaguar's market position and drive growth for its plant-based products, particularly crofelemer.
Jaguar Health (NASDAQ:JAGX) granted 60,000 restricted stock units (RSUs) to New Employee 1 and 12,500 RSUs to New Employee 2 as an inducement for their employment effective June 27, 2022. The RSUs for New Employee 1 will vest fully after one year, while those for New Employee 2 will vest equally over three years. This initiative was approved by the Compensation Committee and is contingent on the employees' continued service with Jaguar. The company focuses on developing sustainable, plant-based medicines for gastrointestinal distress.
Jaguar Health has signed an exclusive license and service agreement with SynWorld Technologies to market Canalevia for treating diarrhea in dogs in China. The agreement includes $5 million in license fees and $5 million in stock purchases over two years. Jaguar is set to receive 60% of profits from sales, increasing to 80% if they cover regulatory costs. The Chinese pet market is projected to reach $70.5 billion by 2023. This agreement aligns with Jaguar's goals for expanding Canalevia's availability and supporting its human pipeline development.
Jaguar Health (NASDAQ:JAGX) announced the online availability of a presentation by Dr. Mohamad Miqdady on Short Bowel Syndrome (SBS) from the Elite Ped-GI Congress in Abu Dhabi, held from May 19-21, 2022. The presentation emphasizes the severe impacts of SBS and congenital diarrheal disorders (CDD), for which current treatment options are limited. The company’s subsidiary, Napo Therapeutics, received orphan-drug designations in the EU and the US for crofelemer, offering hope for patients. The congress aims to update healthcare professionals on pediatric gastroenterology.
Jaguar Health (NASDAQ:JAGX) announced its participation in the ACVIM Forum from June 23-25, 2022, in Austin, TX, to promote Canalevia-CA1, its FDA-conditionally approved treatment for chemotherapy-induced diarrhea in dogs. This product is crucial as many veterinarians report CID impacts chemotherapy plans, highlighting an unmet need. Canalevia-CA1 is derived from the Croton lechleri tree and offers a novel treatment option for affected dogs. The product is available through major veterinary distributors, supporting its commercial launch.
Jaguar Health (NASDAQ:JAGX) announced the publication of an article on June 8, 2022, highlighting the critical need for managing diarrhea in cancer patients, which can affect 50% to 100% of patients undergoing treatment. The article underscores that uncontrolled diarrhea can lead to significant health issues and impact patient quality of life. Jaguar's crofelemer product is in a pivotal Phase 3 trial for preventing diarrhea in adults, while its Canalevia-CA1 for dogs has conditional FDA approval. The company emphasizes the urgency of addressing this side effect for improved treatment outcomes.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the approval of all four proposals at its 2022 Annual Meeting of Stockholders held on June 10, 2022. The details of the proposals are available in the definitive proxy statement filed with the SEC. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues, including Mytesi®, which is specifically for noninfectious diarrhea in HIV/AIDS patients. The company aims to expand access to its products in Europe through its subsidiary Napo Therapeutics.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
